# Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE

> **NCT05001737** · PHASE3 · COMPLETED · sponsor: **Swedish Orphan Biovitrum** · enrollment: 33 (actual)

## Conditions studied

- Macrophage Activation Syndrome
- Secondary Hemophagocytic Lymphohistiocytosis
- Still Disease
- Systemic Lupus Erythematosus
- SJIA
- AOSD
- MAS

## Interventions

- **DRUG:** Emapalumab

## Key facts

- **NCT ID:** NCT05001737
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-15
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-06-04
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05001737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05001737, "Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05001737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*